Ecteinascidin 743: A novel anticancer drug with a unique mechanism of action

Anti-Cancer Drugs

Volumn 13, Issue 6, 2002, Pages 545-555

  Aune, Gregory J ^a   Furuta, Takahisa ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer chemotherapy; DNA alkylation; DNA binding; DNA repair; Minor groove binder; Transcription

Indexed keywords

ANTHRAMYCIN; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CISPLATIN; CYCLOSPORIN; DIAZEPAM; DOXORUBICIN; GUANINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; NSC 648766; NSC 701549; PHTHALASCIDIN; SAFRAMYCIN; TRABECTEDIN; UNCLASSIFIED DRUG; VERAPAMIL; 1,3 DIOXOLANE DERIVATIVE; ALKYLATING AGENT; BACTERIAL DNA; ISOQUINOLINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DNA INTERACTION; DRUG MECHANISM; EXCISION REPAIR; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SARCOMA; TRANSCRIPTION TERMINATION; ANIMAL; CELL; CHEMISTRY; DNA DAMAGE; DRUG EFFECT; DRUG RESISTANCE;

ANIMAL; ANTINEOPLASTIC AGENTS, ALKYLATING; CELLS; CLINICAL TRIALS; DIOXOLES; DNA DAMAGE; DNA, BACTERIAL; DRUG RESISTANCE, NEOPLASM; HUMAN; ISOQUINOLINES; ANIMALS; HUMANS; TETRAHYDROISOQUINOLINES;

EID: 0036021010     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200207000-00001     Document Type: Review

References (56)

1. Antitumor compounds from tunicates
2. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo
3. Ecteinascidins: Putative biosynthetic precursors and absolute stereochemistry
4. Enanthioselective total synthesis of ecteinascidin 743
5. Phthalascidin a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743
6. Reaction of anthramycin with deoxyribonucleic acid
7. Pyrrol[1,4]benzodiazepine antibiotics. Proposed structures and characteristics of the in vitro deoxyribonucleic acid adducts of anthramycin, tomaymycin, sibiromycin and neothramycins A and B
8. DNA sequence specificity of the pyrrolo[1,4]benzodiazepine antitumor antibiotics. Methidiumpropyl-EDTA-iron(II) footprinting analysis of DNA binding sites for anthramycin and related drugs
9. Molecular mechanisms of binding and single-strand scission of deoxyribonucleic acid by the antitumor antibiotics saframycins A and C
10. 2 in the DNA minor groove by ecteinascidin 743 a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata
11. 2
12. Molecular mechanism of binding of pyrrolo(1,4)benzodiazepine antitumour agents to deoxyribonucleic acid - Anthramycin and tomaymycin
13. Reaction of anthramycin with DNA. Biological consequences of DNA damage in normal and xeroderma pigmentosum cell
14. Molecular basis for the DNA sequence selectivity of ecteinascidin 736 and 743: Evidence for the dominant role of direct readout via hydrogen bonding
15. Differential rates of reversibility of ecteinascidin 743-DNA covalent adducts from different sequences lead to migration to favored bonding sites
16. Ecteinascidin 743: A minor groove alkylator that bends DNA toward the major groove
17. Bending of DNA upon binding of ecteinascidin 743 and phtalascidin 650 studied by unrestrained molecular dynamics simulations
18. Increased DNA binding specificity for antitumor ecteinascidin 743 through protein-DNA interactions?
19. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression
20. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650
21. Ecteinascidin-743 (ET-743) a natural marine compound with a unique mechanism of action
22. Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: Ecteinascidin 743 isohomohalichondrin-B and LL-15
23. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of a mean graph and COMPARE algorithm
24. Modulation of transcription factor - DNA interactions by anticancer drugs
25. Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA
26. Molecular approaches to achieving control of gene expression by drug intervention at the transcriptional level
27. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
28. Ecteinascidin 743 a transcription-targeted chemotherapeutic that inhibits MDR1 activation
29. Okadaic acid induces transcription of junB through a CCAAT box and NF-Y
30. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
31. Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA
32. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
33. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent
34. Molecular mechanisms of nucleotide excision repair
35. Mechanisms of transcription-coupled DNA repair
36. Poisoning of human DNA topoisomerase I by ecteinascidin 743 an anticancer drug that selectively alkylates DNA in the minor groove
37. Benzo[a]pyrene epoxide adducts in DNA are potent inhibitors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages
38. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
39. ATM genome stability neuronal development and cancer cross paths
40. Quality control by DNA repair
41. XRCC1 keeps DNA from getting stranded
42. Loss of heterozygosity of nudeotide excision repair factors in sporadic ovarian colon and lung carcinomas: Implication for their roles of carcinogenesis in human solid tumors
43. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
44. Activity of Ecteinascidin 743 and synergism with doxorubicin and vincristine in P-glycoprotein/MDR1 overexpressing cell lines
45. Sequence-dependent enhancement of cytotoxicity produced by Ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells
46. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents
47. ET-743 (PharmaMar/NCI/Ortho Biotech)
48. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies
49. Phase I and pharmacokinetic study of ecteinascidin-743 a new marine compound administered as a 24-hour continuous infusion in patients with solid tumors
50. Ecteinascidin-743: A marine-derived compound in advanced pretreated sarcoma patients - Preliminary evidence of activity
51. Phase I and pharmacokinetic study of Et-743 a minor groove DNA binder administered weekly to patients with advanced cancer
52. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies
53. Population pharmacokinetics of the novel marine derived anti-cancer agent ecteinascidin 743 in two phase II studies using non-linear mixed effects modeling (NONMEM)
54. Ecteinascidin-743 (Et-743) induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II pharmacokinetic studies in the USA
55. Et-743 is an active drug in adult soft-tissue sarcoma (STS): A STBSG-EORTC phase II trial
56. Ecteinascidin (Et-743) given as a 24 hour (h) intravenous continuous infusion (IVCI) every 3 weeks: Results of a phase II trial in patients (pts) with pretreated soft tissue sarcomas (PSTS)